E3S Web Conf.
Volume 218, 20202020 International Symposium on Energy, Environmental Science and Engineering (ISEESE 2020)
|Number of page(s)||6|
|Section||Environmental Chemistry and Environmental Pollution Analysis and Control|
|Published online||11 December 2020|
COVID-19’s Pathways to Human Central Nervous System and Relevant Drug Treatment
Pennsylvania State University, Eberly College of Science State College Pennsylvania, 16802, USA
* Corresponding author. Email: email@example.com
COVID-19, also known as Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV2), is a severe disease. It can cause different types of symptoms including shortness of breath, fever, cough, fatigue and sore throat. Older adults and people who have severe underlying medical conditions like heart or lung disease or diabetes seem to be at higher risk to develop more complex complications due to the infection. Until August 6th, 2020, COVID-19 has caused 700, 000 deaths across the Earth; however, the actual death number could be higher than 700,000. COVID-19’s origin is still remained unknown, but the speculation is targeted to bats or pangolins. Although COVID-19 is a disease target human’s respiratory system, based on the research and clinical cases of COVID-19, evidence shows that COVID-19 can also invade human’s central nervous system (CNS).
© The Authors, published by EDP Sciences, 2020
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.